Apply for Funding Guidance for Applicants The Cure Parkinson’s Trust (CPT) funds and facilitates laboratory or clinical research projects with the potential to advance knowledge that might lead to a cure for Parkinson’s disease. We only accept research applications that meet the following criteria: Disease modifying (slow, stop, reverse) Translate into clinic (Phase 2b trial) within 5 years We DO NOT accept projects which solely focus on symptomatic aspects of Parkinson’s. Please read our full guidance for applicants to ensure that your project complies with our strict funding objectives before requesting a grant application form. We are a member of the Association of Medical Research Charities (AMRC) which is recognised as a quality mark demonstrating that vigorous peer review* processes are in place ensuring that only the highest quality of research is supported. There are many legitimate areas of research into Parkinson’s that do not fall within the remit of CPT. We do, however, welcome enquiries from researchers who seek clarification on the suitability of projects CPT would consider for funding. * In 2017 we approved 16% of new projects submitted to us that year, or 45% of the projects which were sent for peer review – meaning that £1,072,500 was approved to fund new research projects. An additional £150,899 was approved as extension funding of existing, ongoing research. The Process Applicants for grant funding are invited to submit their full proposal including budgets using the relevant forms (see the Applications Forms section below). Applications will be considered according to a number of criteria including their appropriateness to the central aim of The Cure Parkinson's Trust (CPT) i.e. their proximity to cure, originality, the potential clinical impact and achievability. If the proposed project is considered appropriate to the charity’s objectives, it will first undergo a process of internal evaluation. The proposal is then sent for external peer review. At least two detailed external peer reviews are sought using CPT's external peer review protocol completed by our advisory panel and other acknowledged world experts in Parkinson’s research and treatment. If a compound is part of a proposal, an external commercial review may also be sought by trustees. Following external peer review, the proposed project application is then reviewed by the research committee (see below). The research committee prioritises and makes recommendations to the board of trustees which in turn make final funding decisions. Application Forms Before applying to CPT, or requesting an application form, please ensure that your project complies with our strict funding objectives (guidelines stated above). Applicants are invited to submit a full proposal, including budgets to Leah Mursaleen. Please email Leah for an application form or download and print this form. If the project features a drug, please also complete the Drug CV Form. Our research committee meets four times a year. The remaining application date deadlines for 2019 are: Thursday 17th October Please also read our Terms and Conditions for Grant Funding. ** NOTE TO APPLICANTS - The Silverstein Foundation for Parkinson’s with GBA seeks to support research that will study and develop cell transplant therapies for Parkinson’s Disease. Specifically, the Silverstein Foundation is seeking proposal applications for cell transplant therapies with disease modifying potential and/or the potential to significantly improve symptomatic treatment beyond standard of care in GBA-related Parkinson’s Disease. Areas of Interest - The Silverstein Foundation encourages proposals with a translational focus and a defined plan for moving toward clinical utility for patients. For more information click here. The Research Committee Professor Alasdair Coles, Our research committee is chaired by Professor Alasdair Coles, Honorary Consultant Neurologist, Cambridge University Hospitals. Alasdair mainly treats people with multiple sclerosis also seeing people with general neurological problems and those with inflammatory diseases of the brain. Professor Roger Barker, is the Professor of Clinical Neuroscience at the University of Cambridge and Consultant Neurologist at the Addenbrooke's Hospital Cambridge. He is a PI in the MRC- Welcome Trust Stem Cell Institute in Cambridge and the new Director of the MRC funded UKRMP Stem and Engineered cell hub. His research seeks to better define the clinical heterogeneity of two common neurodegenerative disorders of the CNS- namely Parkinson's and Huntington's disease - and their treatment especially with experimental cell and gene based approaches. Dr Camille Carroll, Honorary Consultant Neurologist at Plymouth Hospitals NHS Trust. Camille is the chief investigator of the first multicentre Linked Clinical Trials (LCT) trial in the UK – PD STAT - and is also involved in other LCT studies. She is National Specialty Lead for Neurodegenerative Diseases for the Clinical Research Network and leads the Parkinson’s service in Plymouth, covering West Devon and East Cornwall. Dr Michael Hurley, Research Fellow at the University of Southampton who has been a strong supporter and loyal adviser to the charity since it began.Dr. Tilo Kunath, Senior Research Fellow and Group Leader at MRC Centre for Regenerative Medicine Anthony Temple, is a recently retired QC and was a deputy High Court Judge. For 12 years he chaired the Board of Pentathlon GB, the National Governing Body for the Olympic sport of Modern Pentathlon. Tony is particularly interested in the process and effectiveness of our project funding decisions and his aims include contributing well-informed views as a person with Parkinson’s to the Committee. Dr John Warren, is a clinical scientist who established Medicines Assessment Ltd as a pharmaceutical consultancy in 2011. He advises multiple pharmaceutical companies on clinical development. Dr Alan Whone, Consultant Senior Lecturer in Movement Disorders Neurology at the University of Bristol and Southmead Hospital, Bristol. Dr Richard Wyse, Dr Simon Stott, Dr Joy Duffen, Helen Matthews and Leah Mursaleen - The Cure Parkinson's TrustClick here for more details of our research committee.